Repositioning Candidate Details
| Candidate ID: | R0341 |
| Source ID: | DB01162 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Terazosin |
| Synonyms: | |
| Molecular Formula: | C19H25N5O4 |
| SMILES: | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 |
| Structure: |
|
| DrugBank Description: | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837]. |
| CAS Number: | 63590-64-7 |
| Molecular Weight: | 387.4329 |
| DrugBank Indication: | Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label]. |
| DrugBank Pharmacology: | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocker[FDA Label][A176831,A176837]. |
| DrugBank MoA: | Terazosin is selective for alpha-1-adrenoceptors but not their individual subtypes[A5212,A5457]. Inhibition of these alpha-1-adrenoceptors results in relaxation of smooth muscle in blood vessels and the prostate, lowering blood pressure and improving urinary flow[A176831,A176837,A5212,A5457]. Smooth muscle cells accounts for roughly 40% of the volume of the prostate and so their relaxation reduces pressure on the urethra[A176837]. It has also been shown that catecholamines induce factors responsible for mitogenesis and alpha-1-adrenergic receptor blockers inhibit this effect[A176837]. A final long term mechanism of terazosin and other alpha-1-adrenergic receptor blockers is the induction of apoptosis of prostate cells[A176837]. Treatment with terazosin enhances the expression of transforming growth factor beta-1 (TGF-beta1), which upregulates p27kip1, and the caspase cascade[A176837,A176840]. |
| Targets: | Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Transforming growth factor beta-1; Potassium voltage-gated channel subfamily H member 2; Potassium voltage-gated channel subfamily H member 6; Potassium voltage-gated channel subfamily H member 7 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|